biolitec AG: biolitec AG achieved consolidated revenue of Euro 6.2 million for the first three months of the fiscal year 2009/2010 - EBIT rises to Euro 0.63 million

biolitec AG / Quarter Results/Interim Report

30.11.2009 

Dissemination of an Ad hoc announcement according to § 15 WpHG,
transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

 

biolitec AG achieved consolidated revenue of Euro 6.2 million for the first
three months of the fiscal year 2009/2010 - EBIT rises to Euro 0.63 million

Jena, November 30th, 2009 - biolitec AG, Jena, listed in the Prime Standard
of the Frankfurt stock exchange (ISIN DE0005213409), realized a
consolidated revenue of Euro 6.2 million for the first quarter of the
fiscal year 2009/2010. The sales revenue, according to expectation,
amounted slightly below the revenue for the first quarter of the fiscal
year 2008/2009. In Q1 of the fiscal year 2009/2010 some cost saving
capabilities became visible in the operating profit and the figures, which
have been realized already in the last six month of the past fiscal year.

The gross profit amounted to Euro 4.5 million (last fiscal year: Euro 5.2
million) and EBIT amounted to Euro 0.63 million (previous year: Euro 0.51
million). R&D expenditures for the first three months of the fiscal year
2009/2010 of Euro 0.65 million (about 10% of sales) compared to the
previous year (Euro 1,05 million) have been reduced substantially, but
remained on the required level to ensure the groups' long term growth and
profitability. Distribution costs also could have been reduced
significantly to Euro 2.1 million compared to Euro 2.95 million in the last
year's period.

The revenue posted by the laser segment of Euro 1.3 million in Q1 was lower
than in the prior year (Euro 2.4 million) mainly due to the investment
restraint. The fiber optics and laser probes segment contributed Euro 4.7
million to the group's total revenue and exceeds the previous year's level,
which is a sign of a persistent good and increasing number of treatments.

Mainstays of sales are the BPH laser treatment LIFE(TM) and the endoluminal
laser treatment of veins (ELVeS(TM)).

biolitec AG's major revenues were again generated in Europe and North
America. With Euro 2.75 million, sales in North America were on previous
year's level, contributing 44% of total sales. European sales amounted to
Euro 2.54 million (previous year: Euro 3.7 million), in Asia and ROW
biolitec was able to slighty increase revenues to Euro 0.9 million.
biolitec AG expects sales growth to pick up during the fiscal year, if the
propensity to invest again rises. Due to the improved cost structure that
way, compared to the previous year, the profit shall increase.

With HeLP(TM) (Haemorrhoid Laser Procedure), a procedure for the atrophy of
haemorrhoidal arteries, a minimally invasive and secure intervention
(applied for a patent of biolitec) now is possible. By means of one-way
probes and selective laser energy and fiber optics systems, haemorrhoidal
arteries can be identified and with the help of photocoagulation the
haemorrhoids can be shrinked. Because that is an essential innovation for
the treatment of a widespread disease, biolitec sees in it a considerable
sales potential for the next fiscal years.

Due to the staff reduction and the reduced costs in total, inventories and
working capital will further decrease in the coming quarters and the cash
holdings will increase further.


30.11.2009  Financial News distributed by DGAP. Media archive at
www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0) 3641 508 550
Fax:          +49 (0) 3641 508 599
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------